

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Zolbetuximab with chemotherapy for untreated claudin 18.2 positive HER2-negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma ID5123

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
Astellas Pharma (Zolbetuximab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups Black Health Agency for Equality Cancer Black Care Cancer Equality Cancer 52 GIST Cancer UK GUTS UK Heartburn Cancer UK Helen Rollason Cancer Charity Independent Cancer Patients Voice Less Survivable Cancers Taskforce Macmillan Cancer Support Maggie's Centres Marie Curie Ochre Oesophageal Patients Association South Asian Health Foundation	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
Specialised Healthcare Alliance	Possible comparator companies
 Tenovus Cancer Care The oesophageal Patients Association Together Support Group United Kingdom and Ireland Oesophagogastric Cancer Group 	 Accord Healthcare (capecitabine, cisplatin, epirubicin, fluorouracil, oxaliplatin) Bristol-Myers Squibb (nivolumab) Dr. Reddy's Laboratories (capecitabine)
 Healthcare professional groups Association of Anaesthetists Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland 	 Glenmark Pharmaceuticals (capecitabine) Hospira UK (cisplatin, fluorouracil, oxaliplatin) Medac (epirubicin, fluorouracil, oxaliplatin) Morningside Healthcare (capecitabine)

Provisional stakeholder list for evaluation of zolbetuximab with chemotherapy for untreated claudin 18.2 positive HER2-negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma ID5123. Issue date: January 2024




Consultees	Commentators (no right to submit or appeal)
 British Association of Surgical Oncology British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society of Gastroenterology Cancer Research UK Primary Care Society for Gastroenterology Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 MSD (pembrolizumab) Pfizer (epirubicin) Ranbaxy (oxaliplatin) Sandoz (cisplatin) Seacross Pharmaceuticals (epirubicin, oxaliplatin) Relevant research groups Cochrane UK Cochrane Gut Group Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.